The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis

Show simple item record

dc.contributor.author Leprun, Pauline M. B.
dc.contributor.author Clarke, Gerard
dc.date.accessioned 2019-05-24T08:53:57Z
dc.date.available 2019-05-24T08:53:57Z
dc.date.issued 2019-05-10
dc.identifier.citation Leprun, P. M. B. and Clarke, G. (2019) 'The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis', Current Opinion in Pharmacology, 49, pp. 17-23. doi: 10.1016/j.coph.2019.04.007 en
dc.identifier.volume 49 en
dc.identifier.startpage 17 en
dc.identifier.endpage 23 en
dc.identifier.issn 1471-4892
dc.identifier.uri http://hdl.handle.net/10468/7974
dc.identifier.doi 10.1016/j.coph.2019.04.007 en
dc.description.abstract New frontiers for host-microbe interactions continue to emerge as our knowledge of the adult gut microbiome in health and disease is continually supplemented and improved. Alterations in the gut microbiota composition in irritable bowel syndrome (IBS) are now linked to symptom severity while population-based evidence linking gut microbiome signatures to depression is an important new landmark. The effects of drugs on gut microbiome composition are also becoming clearer. Meanwhile, preclinical studies have delineated the influence of the gut microbiome at a structural and activity level in distinct brain regions. Bacterial metabolites, such as tryptamine, can activate specific receptors to impact gastrointestinal motility. These recent studies bring into focus the future implications for therapeutic targeting of the microbiomeâ gutâ brain axis. en
dc.description.sponsorship Health Research Board (Grant number ILP-POR-2017-013); Air Force Office of Scientific Research (Grant number FA9550-17-1-006) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier Ltd. en
dc.relation.uri http://www.sciencedirect.com/science/article/pii/S1471489218301516
dc.rights © 2019, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license. en
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ en
dc.subject Gut microbiome en
dc.subject Depression en
dc.subject Tryptamine en
dc.title The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Gerard Clarke, Psychiatry, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.clarke@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by request of the publisher. en
dc.check.date 2020-05-10
dc.date.updated 2019-05-24T08:45:04Z
dc.description.version Accepted Version en
dc.internal.rssid 486413852
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Health Research Board en
dc.contributor.funder Air Force Office of Scientific Research en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Current Opinion in Pharmacology en
dc.internal.copyrightchecked Yes
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress g.clarke@ucc.ie en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/ en
dc.identifier.eissn 1471-4973


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license. Except where otherwise noted, this item's license is described as © 2019, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement